Previous close | 0.4500 |
Open | 0.4800 |
Bid | N/A x N/A |
Ask | N/A x N/A |
Day's range | 0.4500 - 0.4500 |
52-week range | 0.0003 - 3.1000 |
Volume | |
Avg. volume | 12 |
Market cap | 35.112M |
Beta (5Y monthly) | 2.14 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.5800 |
Earnings date | 22 Mar 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
PARIS, May 07, 2024--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, announced that it will hold its Annual General Meeting on May 29, 2024, at 9:00 am CEST at the Company’s headquarters, 74 rue du Faubourg Saint-Antoine, 75012 Paris, France.
PARIS, May 07, 2024--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible) (the "Company"), a biopharma Company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, announced today the resumption of the trading of the Company’s shares following the success of its Offering (as defined below), through (i) a capital increase reserved to specialized investors and (ii) a c
PARIS, April 18, 2024--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced the filing of its 2023 Universal Registration Document (URD) in English with the French market authority (Autorités des Marchés Financiers, or AMF) under the reference D.24-0299.